AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05959031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kTMP
Description: a new non-invasive brain stimulation tool
Study NCT05959031 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham kTMP
Description: a new non-invasive brain stimulation tool with sham setting selected
Study NCT06335498 — intervention group
Intervention type: DEVICE
Intervention: ECG co-measurement
Description: Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
Study NCT06335498 — intervention group
Intervention type: DEVICE
Intervention: Periodic ECG triggered measurement
Description: Subject triggers AFGen1 to perform an extended measurement during wear period
Study NCT05508685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT and Cognitive Reassessment
Description: Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
Study NCT05508685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT group
Description: Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
Study NCT05508685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emotional regulation strategy group
Description: Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
Study NCT05508685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
Study NCT04910074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
Study NCT04910074 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dummy LLLT
Description: The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
Study NCT04722601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
Study NCT04722601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: An oral form of azacitidine (a standard chemotherapy drug).
Study NCT06224322 — intervention group
Intervention type: OTHER
Intervention: Assesment Scale
Description: Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
Study NCT04024293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldfish (GF)
Description: The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
Study NCT04899817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: The drug is given after induction of general anesthesia
Study NCT04899817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: The drug is given after induction of general anesthesia
Study NCT06105567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training given according to the health promotion model by applying the Philips 66 technique
Description: The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
Study NCT04569695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar Pressure Biofeedback Gait Training
Description: Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target.
Study NCT05965336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propulsion Biofeedback Gait Training
Description: Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
Study NCT05698121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapriXpress
Description: The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
Study NCT04981977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Transitions Intervention
Description: CTI is delivered by a trained Care Transitions Coach (Coach) who works closely with patients to ensure a smooth transition from hospital to home following an acute hospitalization. The patient, caregiver, and Coach work together to maximize the involvement of interdisciplinary experts, ensuring that the appropriate professionals are involved, issues are addressed, goals are understood, and the discharge care plan is executed correctly. There are three aspects to CTI; the first is the initial hospital visit, followed by an in-home visit, concluding with telephone follow-up over a 28-day period. During these visits, the Coach focuses on four conceptual areas, referred to as pillars (i.e., Personal Health Record, Medication Management, Red Flags, and Physician Follow up). The Coach ensures the patient understands and utilizes the Personal Health Record to facilitate communication and ensure continuity of care plan across providers and settings.
Study NCT04981977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Transitions Intervention and Peer Support
Description: The PS intervention for this study is based upon the principles of motivational interviewing, which is a person-centered, goal-directed method to enhance intrinsic motivation for change by exploring and resolving ambivalence. A recent meta-analysis found the mean effect size for MI to be significantly larger for racial and ethnic minority samples (0.79 vs. 0.26) as compared to non-Hispanic Whites, highlighting its potential benefit and cultural relevance for minority populations. Patients in this arm of the study will receive the 28-day CTI intervention with a 2-month long Peer Support (PS) intervention provided by trained peer educators (PEs).
Study NCT04981977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The researchers will follow a control group of patients who meet study inclusion criteria. These older adults will participate in the traditional discharge case-management offered by the hospital where they were admitted and discharged. UC at our three partner hospitals consists of: (1) routine inpatient nurse intake that includes screening about housing, substance abuse, and functional status; (2) medication reconciliation performed by treating practitioners; (3) discharge patient education provided by inpatient nurses; (4) a list of resources for safety-net clinics and community-based services; and (5) for patients with severe chronic illness (e.g. heart failure) there may be a planned home visit by a nurse practitioner.
Study NCT04083001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTR4132MD
Description: According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours.
Study NCT05873361 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
Study NCT05061576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care advice on physical activity
Description: Oral advice on exercise from a physician.
Study NCT05061576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured advice on physical activity
Description: A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
Study NCT06301061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equistasi®
Description: Four devices will be attached to the skin according the indication of the investigators for 6 hours/day every day except Thursday and Sunday
Study NCT06301061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Four devices similar to the active one but not able to deliver the microvibration will be applied to the patients
Study NCT06301061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin; Pregabalin; Duloxetine; Amitriptyline
Description: Patients will be treated with drugs (gabapentinoids, Serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, opioids) according to guidelines.
Study NCT04661033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study NCT05276674 — intervention group
Intervention type: DEVICE
Intervention: ZNN Bactiguard Retrograde Femoral Nail
Description: Femoral fracture internal fixation.
Study NCT05279157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient
Study NCT05279157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient
Study NCT04704258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI (Transcatheter Aortic Valve Implant)
Description: Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures
Study NCT04704258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLOWer Embolic Protection System
Description: FLOWer Embolic Protection System
Study NCT05752175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01
Description: WPV01 tablets
Study NCT05752175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT06430788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab is an interferon gamma (IFNγ) blocking antibody
Study NCT05572827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
Study NCT05344976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSLN STAR-T cells
Description: Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
Study NCT05263817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA CAR T-cells
Description: Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
Study NCT05931913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex
Description: TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern
Study NCT05931913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure with Response Prevention
Description: ERP will be delivered daily, immediately following TMS
Study NCT05931913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with Response Prevention
Description: ERP will be delivered daily, immediately following TMS
Study NCT05931913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation: Sham
Description: Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex
Study NCT05931913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area
Description: TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
Study NCT05432102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse oxymetry
Description: Diagnostic intervention to diagnose OSA.
Study NCT05432102 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory polygraphy
Description: Diagnostic intervention to diagnose OSA.
Study NCT04334915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc Mesylate (CVC)
Description: Administered orally
Study NCT04334915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04846894 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA-11 PET/CT imaging
Description: Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
Study NCT05697055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azvudine
Description: 5mg orally, once a day, for no more than 14 days
Study NCT05697055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir-Ritonavir
Description: Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
Study NCT04515537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),
Description: Patient use 2 capsules 3 time a day by oral.
Study NCT04515537 — intervention group
Intervention type: PROCEDURE
Intervention: Infiltrtion of SVf
Description: After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
Study NCT06134791 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04485091 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 20% TCM and PBM
Description: The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.
Study NCT04485091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 20% TCM and PBM placebo
Description: The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
Study NCT05032313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IUO CLPD Limited Panel
Description: This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
Study NCT04274023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
Study NCT05296382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem tablet form
Description: Tebipenem tablets will be administered intact or crushed
Study NCT05296382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tube feeds
Description: Tebipenem tablets will be administered with or without tube feeds
Study NCT04684303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch radiofrequency ablation neurotomy
Description: Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
Study NCT05300477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Carbonic Anhydrase Inhibitor
Study NCT05300477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Hormone for red blood cell
Study NCT06146816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation treatment in the infrared (IR) range.
Description: The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
Study NCT06146816 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: photobiomodulation treatment in the infrared (IR) range.
Description: The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
Study NCT04684303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch cryo ablation neurotomy
Description: Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
Study NCT04944888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
Study NCT04944888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: immune checkpoint inhibitor (physician decided).
Study NCT04774796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.